CASI Pharmaceuticals, Inc.
4.80%
992,638
1962738
G1933S101
Sep 29, 2025
Jan 20, 2026, 09:33 AM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Zhou Quan | Individual | 4.80% | 992,638 | 76,788 | 915,850 |
| IDG-Accel China Growth Fund III L.P. | Partnership | 4.50% | 915,850 | 855,222 | 60,628 |
| IDG-Accel China III Investors L.P. | Partnership | 4.50% | 915,850 | 60,628 | 855,222 |
| IDG-Accel China Growth Fund III Associates L.P. | Partnership | 4.50% | 915,850 | 855,222 | 60,628 |
| IDG-Accel China Growth Fund GP III Associates Ltd. | CO | 4.50% | 915,850 | 915,850 | 0 |
| Ho Chi Sing | Individual | 4.50% | 915,850 | 0 | 915,850 |
Disclosure Items (2)
Ordinary Shares, par value US$0.0001 per share
CASI Pharmaceuticals, Inc.
1701-1702, CHINA CENTRAL OFFICE TOWER 1, BEIJING, F4, 100025
Item 5(a) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: The aggregate number and percentage of the Ordinary Shares beneficially owned by each Reporting Person is set forth on the cover pages to this Statement on Schedule 13D and is incorporated by reference herein. The ownership percentage appearing on such pages has been calculated based on a total of 20,548,273 Ordinary Shares of the Issuer outstanding as of September 30, 2025, as disclosed in the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on November 14, 2025. The Reporting Persons disclaim membership in any "group" with any person other than the Reporting Persons. The filing of this Statement on Schedule 13D by the Reporting Persons shall not be considered an admission that such Reporting Persons, for the purpose of Section 13(d) of the Exchange Act, are the beneficial owners of any of the Ordinary Shares covered in this Statement on Schedule 13D, and the Reporting Persons expressly disclaim such beneficial ownership.
Item 5(b) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: For each Reporting Person, the number of the Ordinary Shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on the cover pages to this Statement on Schedule 13D, and are incorporated herein by reference.
Item 5(c) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: None of the Reporting Persons has engaged in any transactions in the Issuer's securities during the past sixty days other than as disclosed herein.
Item 5(e) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: Each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the Ordinary Shares of the Issuer on September 30, 2025.